

## Jardiance prevails where Entresto could not



[Madeleine Armstrong](#)

Right now the only drug approved for heart failure with preserved ejection fraction is Novartis's Entresto – [and only in some patients](#). This could be about to change, with Lilly and Boehringer Ingelheim reporting a topline win in HFpEF today with their SGLT2 inhibitor Jardiance. The companies are saving details of the [Emperor-Preserved trial](#) for the European Society of Cardiology meeting in August, and the magnitude of benefit will be closely watched. By way of comparison, [Entresto showed a 13% reduction](#) in the risk of cardiovascular death and heart failure hospitalisations; this narrowly missed statistical significance but was enough for the FDA to broaden that drug's label. Hopes will now be building for a class effect with the SGLT2s in HFpEF; a benefit [had already been suggested with Lexicon's SGLT1/2 inhibitor sotagliflozin](#), while the [Deliver trial of AstraZeneca's Farxiga](#) is set to complete early next year. Jardiance, currently marketed for type 2 diabetes, is forecast to sell over \$5bn by 2026, according to *Evaluate Pharma* sellside consensus, but this might soon get a bump. Lilly and Boehringer do not have too long to benefit from any heart failure approvals, though, with the drug set to come off patent in 2028.

### Selected studies in HFpEF

Product	Company/ies	HFpEF trial	Data	Note
Entresto	Novartis	<a href="#">Paragon</a>	13% risk reduction in CV death & HHF, p=0.059	<a href="#">Approved for HF pts with LVEF "below normal"</a>
Sotagliflozin	Lexicon	<a href="#">Soloist &amp; Scored</a>	Pooled analysis: 37% risk reduction in CV death, HHF & urgent HF visit, p=0.009	2021 filing planned in HF with T2D
Jardiance	Lilly/Boehringer	<a href="#">Emperor-Preserved</a>	Met primary endpoint of time to CV death or HHF; full data at ESC 2021	2021 filing planned in HFpEF; filed in HFrEF with decision due 2021
Farxiga	Astrazeneca	<a href="#">Deliver</a>	Completes Jan 2022 (prev Nov 2021)	Approved in HFrEF in May 2020
Injectable sema 2.4mg	Novo Nordisk	<a href="#">Step-HFpEF</a> in HFpEF & obesity*	Completes Mar 2023	
Tirzepatide	Lilly	<a href="#">Summit</a> in HFpEF & obesity	Completes Nov 2023	
Finerenone	Bayer	<a href="#">Finearts-HF</a> in pts with EF ≥40%	Completes Mar 2024	

\*Second ph3 study planned in pts with obesity-related HFpEF & T2DM. HHF=hospitalisation for heart failure; LVEF=left ventricular ejection fraction; T2D=type 2 diabetes. Source: company releases & [clinicaltrials.gov](#).

[More from Evaluate Vantage](#)

Evaluate HQ  
[44-\(0\)20-7377-0800](tel:44-020-7377-0800)

Evaluate Americas  
[+1-617-573-9450](tel:+16175739450)

Evaluate APAC  
[+81-\(0\)80-1164-4754](tel:+8108011644754)

© Copyright 2022 Evaluate Ltd.